Novel Glucose Responsive Insulin for Improved Treatment of Diabetes
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AMIDEBIO, LLC
- Proposal award date
- 2021-03-01
- Contract end date
- 2023-02-28
- UEI
- UN9KNR7J6J77
- Solicitation number
- PA20-260
- Topic code
- NIDDK
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)
- Long-acting Stable Glucagons for Treatment of Hyperinsulinism
- Stable Glucagon for Treatment of Hyperinsulinism
- Stable Glucagon for Treatment of Hyperinsulinism
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
5 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $6,817,932. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services